Tag: non-injectable insulin market size

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Non-injectable Insulin Market Valuation Change Between Now And 2029?

The market for non-injectable insulin has seen swift expansion in the past few years. The industry, which had a value of $1.92 billion in 2024, is projected to increase to $2.14 billion by 2025, representing a compound annual growth rate (CAGR) of 11.1%. Factors like better patient adherence to treatment, the resolution of needle-related fears, improved life quality, simpler administration methods, and steady control of blood sugar levels have contributed to this historic growth.

The market size for non-injectable insulin is set to experience robust expansion in the coming years, with predictions suggesting it will reach $3.11 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 9.8%. This anticipated growth over the forecast period can be credited to ongoing efforts in patient compliance, solutions for persistent needle fear, further life quality augmentation, continued safety upgrades, and the minimization of infection and injury risks. In the same period, key trends to watch include technological advancements, the development of techno-solutional approaches, the merging of digital health, applications of nanotechnology, and combined therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What External And Internal Drivers Are Influencing The Non-injectable Insulin Market?

The escalating issues of obesity and diabetes are anticipated to fuel the expansion of the non-injectable insulin market. Obesity, defined by an excess buildup of body fat typically resulting from an imbalance between caloric intake and energy expenditure, along with diabetes mellitus – commonly known as diabetes, a metabolic disorder group characterized by sustained high blood sugar levels, are both treated by non-injectable insulin. This form of treatment has the potential to ameliorate management by tackling impediments to insulin therapy, offering potential weight management benefits, and introducing more convenient treatment alternatives. For example, the World Heart Federation, a non-governmental organization based in Switzerland, predicts a global obesity spike in 2022, foreseeing the number of children and adults struggling with overweight and obesity rising from an estimated 2.3 billion in 2021 to 2.7 billion by 2025. In addition, a report released by the British Diabetic Association, a UK-based diabetes charity, in April 2023, indicated that in the UK, there are 4.3 million diabetes patients, and over 2.4 million individuals are at a high risk of developing type 2 diabetes. The registration figures for 2021-22 have seen an increase by 148,951 compared to the previous year. Thus, the escalating issues of obesity and diabetes are catalyzing the expansion of the non-injectable insulin market.

Which Segments Define The Structure Of The Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

What Strategic Shifts And Innovations Are Influencing The Non-injectable Insulin Market?

Key players in the non-injectable insulin market are turning their attention towards pioneering advancements in drug delivery technology like the needle-free oral insulin spray. This step is significant in enhancing the lives of those managing their diabetes through numerous insulin injections. A needle-free insulin spray offers a blood glucose regulation method that is convenient and painless, as it can directly be sprayed into one’s mouth. An example of this is when NiedlFree Technologies, a tech platform based in India, unveiled an oral insulin spray named Ozulin in November 2023. The aim of this innovation is to create a more user-friendly response for those living with diabetes. This is particularly relevant for individuals who struggle with traditional insulin injections. Upon approval, Ozulin could revolutionize the diabetic world by providing a more convenient and less painful substitute for insulin injections.

Which Firms Are Making The Biggest Impact In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Is Forecasted To Lead The Non-injectable Insulin Market In The Coming Years?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Non-injectable Insulin Market From 2025 to 2029?

In recent times, the market size for non-injectable insulin has seen a swift expansion. The market is expected to surge from $1.92 billion in 2024 to $2.14 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.1%. Key factors contributing to this growth during the historic period include improvements in patient adherence, mitigation of needle fear, enhancements in quality of life, simplicity in application, and effective control of blood sugar levels.

In the coming years, the market for non-injectable insulin is projected to witness robust expansion. It is expected to rise to “$3.11 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 9.8%. The forecasted growth is due to several factors, including the emphasis on maintaining patient compliance, resolving persistent fear of needles, enhancing quality of life, increasing safety measures, and minimizing the risk of infections and injuries. Key trends expected during this period are advancements in technology, evolutionary technological solutions, incorporation of digital health, application of nanotechnology, and combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Elements Are Contributing To Growth In The Non-injectable Insulin Market?

The escalating problems of obesity and diabetes are anticipated to fuel the expansion of the non-injectable insulin market. Obesity, marked by an abnormal pile-up of body fat due to an imbalance in energy consumption and expenditure, and diabetes mellitus, commonly known as diabetes and distinguished by prolonged periods of high blood sugar levels, are two conditions that increasingly warrant the use of non-injectable insulin. This form of insulin is utilized in the treatment of diabetes and obesity and has the capacity to augment disease management by overcoming obstacles to insulin therapy, providing potential weight management benefits, and supplying more user-friendly treatment alternatives. For example, the World Heart Federation, a non-governmental organization based in Switzerland, projected in 2022 a steep rise in global obesity rates. An estimation reveals that 2.3 billion people, including children and adults, struggled with overweight and obesity issues in 2021, but this figure is expected to escalate to 2.7 billion by 2025. Moreover, a report released by the British Diabetic Association, a diabetes charity based in the UK, revealed in April 2023 that 4.3 million people in the UK have diabetes and over 2.4 million UK residents are at a high risk of developing type 2 diabetes. The 2021-22 registration data shows an increase of 148,951 compared to the past year. This surge in obesity and diabetes thus stands as the driving factor for the expansion of the non-injectable insulin market.

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Which Emerging Trends And Strategic Shifts Are Shaping The Non-injectable Insulin Market?

Leading businesses in the non-injectable insulin market are prioritizing innovative improvements in drug delivery systems, with a focus on painless, needle-free alternatives such as oral insulin sprays, to better the lives of those dependent on multiple insulin injections for their diabetes management. These sprays serve as a convenient method of regulating blood sugar as they can easily be sprayed directly into the patient’s mouth. NiedlFree Technologies, an Indian tech platform, launched Ozulin, an oral insulin spray, in November 2023 as an example of this invention. This spray aims to provide a user-friendly substitute for people with diabetes, especially those who find the traditional insulin injection methods daunting. Ozulin, if approved, has the potential to revolutionalize the treatment of diabetes by offering a more convenient, and painless alternative to insulin injections.

Who Are The Key Contributors To Growth In The Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which Region Is Projected To Lead The Non-injectable Insulin Market By 2025?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Non-injectable Insulin Market From 2025 To 2029?

There has been a significant increase in the market size of non-injectable insulin in the past few years. It is projected to expand from $1.92 billion in 2024 to $2.14 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. The historical growth is due to factors such as better patient adherence, resolution of needle-related fears, improvements in life quality, simplified administration, and consistent control of blood sugar levels.

The market for non-injectable insulin is projected to witness substantial growth in the upcoming years, escalating to a valuation of $3.11 billion by 2029, with a compound annual growth rate (CAGR) of 9.8%. The expansion during the forecast period can be linked to an ongoing focus on patient compliance, enduring solutions for needle fear, additional quality of life enhancements, uninterrupted improvements on safety, and fewer risks related to infection and injury. Key trends during this prognosis phase encompass advancements in technology, development of tech-based solutions, incorporation of digital health, the use of nanotechnology, and combined therapy schemes.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Non-injectable Insulin Market?

The escalating rates of obesity and diabetes are projected to drive the growth of the non-injectable insulin market. Defined by an excessive buildup of body fat due to an imbalance of energy consumed and expended, obesity alongside diabetes, a group of metabolic disorders marked by prolonged high blood sugar levels, are health conditions that non-injectable insulin offers treatment for. Not only can it potentially enhance the management of these diseases by tackling hindrances to insulin therapy, but it can also offer potential weight management benefits and more convenient therapeutic alternatives. For example, data from the World Heart Federation, a Swiss non-governmental organization, predicts a surge in global obesity rates for 2022, with the current figures of 2.3 billion people, including both children and adults, struggling with overweight and obesity issues set to climb to 2.7 billion by 2025. Additionally, according to a report issued in April 2023 by the British Diabetic Association, a UK-based diabetes charity, 4.3 million people in the UK have diabetes, and approximately 2.4 million UK residents are considered high risk for developing type 2 diabetes. The number of registrations for 2021-2022 have experienced an increase of 148,951 from the previous year, hence, contributing to the rising prevalence of obesity and diabetes which are contributing factors to the growth of the non-injectable insulin market.

Which Key Market Segments Comprise the Non-injectable Insulin Market and Drive Its Revenue Growth?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Which Areas Are Leading Regions in the Non-injectable Insulin Market Expansion Across the Globe?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theNon-injectable Insulin Market Over the Coming Years?

Major firms in the non-injectable insulin market are concentrating their efforts on revolutionary progress in drug delivery methods such as a needle-free oral insulin spray. These advancements aim to enhance the management of diabetes for individuals who rely on multiple insulin shots. This type of spray offers a hassle-free and painless method for controlling blood glucose levels since it can be directly sprayed into the mouth. NiedlFree Technologies, a tech platform based in India, launched an oral insulin spray named Ozulin in November 2023. The purpose of this spray is to provide a more approachable solution for people with diabetes, especially for those who find the conventional insulin injection procedures daunting. Once approved, Ozulin could potentially revolutionize the diabetic community by providing a more convenient and painless alternative to insulin injections.

View the full report here:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

How Is the Non-injectable Insulin Market Conceptually Defined?

Non-injectable insulin is a type of insulin that can be administered into the body without the need for injection. These non-injectable forms of insulin aim to offer alternatives to traditional injections, making diabetes management more accessible and potentially improving the overall quality of life for individuals with diabetes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Non-injectable Insulin Market Grown from 2024 to 2025?#_x000D_

The market size for non-injectable insulin has seen a swift increase in recent times. Rising from a valuation of $1.92 billion in 2024, it is projected to reach $2.16 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.1%. The historic growth can be credited to factors like better patient compliance, tackling needle fear, improved quality of life, simple administration methods, and consistent control of blood glucose levels._x000D_

_x000D_

#What Growth Rate Is Anticipated for the Non-injectable Insulin Market in the Coming Years?#_x000D_

The market size for non-injectable insulin is predicted to rapidly expand in the following years, reaching a value of $3.17 billion in 2029 with a compound annual growth rate of 10.1%. This projected growth during the forecast period is linked to ongoing focus on patient adherence, constant solutions for needle fear, improvements in life quality, unceasing enhancement of safety measures, and minimised risks associated with infections and injuries. The forecast period will also see principal trends like the advancement in technology, development of tech-based solutions, incorporation of digital health, application of nanotechnology, and combined therapies._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp_x000D_

_x000D_

#Who Are the Leading Companies in the Non-injectable Insulin Market?#_x000D_

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited_x000D_

_x000D_

#What Are the Key Drivers of the Non-injectable Insulin Market?#_x000D_

Anticipated increases in obesity and diabetes cases are projected to spur the expansion of the non-injectable insulin market. Obesity involves the extreme build-up of body fat, typically due to an energy imbalance between calories ingested and output, while diabetes mellitus, commonly known simply as diabetes, includes a set of metabolic disorders marked by sustained high blood sugar levels. Non-injectable insulin serves as a remedy for diabetes and obesity, with the capacity to enhance control by tackling hurdles to insulin treatment, providing potential weight control benefits and more convenient care options. For instance, as per the World Heart Federation, a Switzerland-domiciled NGO, the global prevalence of obesity is predicted to escalate, with approximately 2.3 billion people in 2021, children and adults included, struggling with being overweight and obesity that’s expected to increase to 2.7 billion by 2025. In addition, in April 2023, a study by the British Diabetic Association, a UK diabetes charity, reported that 4.3 million individuals in the UK have diabetes and over 2.4 million dwellers are at a high risk of developing type 2 diabetes. The enrolment numbers for 2021-22 displayed an increase of 148,951 from the prior year. Consequently, surging obesity and diabetes problems are stimulating the expansion of the non-injectable insulin market._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp_x000D_

_x000D_

#What Are the Key Market Segments in the Non-injectable Insulin Industry?#_x000D_

The non-injectable insulin market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Synthetic Insulin, Semi Synthetic Insulin_x000D_

2) By Product: Pills, Sprays, Other Products_x000D_

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores_x000D_

_x000D_

Subsegments:_x000D_

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin_x000D_

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations_x000D_

_x000D_

#What Are the Latest Trends in the Non-injectable Insulin Market?#_x000D_

Leading firms in the non-injectable insulin industry are concentrating on the development of innovative drug delivery technologies such as needle-free insulin sprays. They’re aimed at enhancing the quality of life for diabetic patients who require frequent insulin injections. A needle-free insulin spray is a hassle-free and painless alternative for blood glucose control and can be conveniently sprayed directly into the mouth. NiedlFree Technologies, a technology company based in India, launched an oral insulin spray called Ozulin in November 2023. Ozulin is aimed at being more user-friendly, especially for people with diabetes who may find conventional insulin injection methods difficult. If it gets approval, Ozulin could significantly transform the diabetes care market by providing a less painless and more convenient alternative to insulin injections._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report_x000D_

_x000D_

#What Are the Key Regional Markets in the Non-injectable Insulin Industry?#_x000D_

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the non-injectable insulin market, and how is it changing globally?_x000D_

2. Who are the major companies in the non-injectable insulin market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the non-injectable insulin market right now?_x000D_

4. Which products or customer segments are growing the most in the non-injectable insulin market?_x000D_

5. What factors are helping or slowing down the growth of the non-injectable insulin market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Non-injectable Insulin Market?

The escalation of obesity and diabetes problems are predicted to fuel the expansion of the non-injectable insulin market. Obesity, which is distinguished by an abnormal accumulation of body fat, typically results from an inconsistency between energy intake and expenditure. Diabetes mellitus, frequently termed merely as diabetes, is a collection of metabolic conditions signified by elevated blood sugar levels over an extended duration. Non-injectable insulin is employed to treat diabetes and obesity and may enhance management by overcoming hurdles to insulin treatment, providing possible weight control advantages, and supplying easier treatment options. For example, the World Heart Federation, a Switzerland-based NGO, forecasts that global obesity prevalence is expected to increase by 2022, with about 2.3 billion people, encompassing children and adults, dealing with being overweight and obesity in 2021, a figure projected to jump to 2.7 billion by 2025. Additionally, a report by British Diabetic Association, a UK-based diabetes charity, reported in April 2023 that in the UK, 4.3 million people have diabetes, and over 2.4 million individuals are at a high risk of developing type 2 diabetes. The enrollment numbers for 2021-22 have swelled by 148,951 in comparison to the prior year. Consequently, the escalating issues of obesity and diabetes are propelling the expansion of the non-injectable insulin market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What is the Predicted Annual Growth Rate of theNon-injectable Insulin Market Impact Industry Trends by 2034?

The market for non-injectable insulin has seen significant growth in recent years. Projected growth from $1.92 billion in 2024 to $2.16 billion in 2025, with a CAGR of 12.1%, evidences this. Factors contributing to the growth include better patient compliance, an answer to needle phobia, improved quality of life, simpler administration, and steadier blood glucose control.

The market size of non-injectable insulin is predicted to undergo swift expansion in the coming years, climbing to a size of $3.17 billion in 2029, experiencing an annual compounded growth rate of 10.1%. This surge in the anticipated period is due to several factors such as ongoing focus on patient adherence, persistent solutions to needle fear, additional improvements in patient quality of life, continual safety upgrades, and minimized chances of infections and injuries. Key trends during the forecast period are expected to be technological developments, advancement of tech solutions, incorporation of digital health, application of nanotechnology, and combined therapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

What New Market Trends Are Reshaping theNon-injectable Insulin Market and Its Opportunities?

Top firms in the non-injectable insulin market are prioritizing novel advancements in drug delivery systems like the needle-free oral insulin spray. Such advancements aim to boost the quality of life for those managing their diabetes through numerous insulin injections. The needle-free insulin spray offers a painless, needle-free method of managing blood sugar levels, with a handy feature that allows direct spraying into the mouth. For instance, in November 2023, NiedlFree Technologies, an Indian tech platform, launched Ozulin, an oral insulin spray. This product is specifically designed to offer an easier alternative for people with diabetes who may struggle with traditional injectable insulin methods. If approved, Ozulin is poised to revolutionize the world of diabetes management with a more convenient and pain-free substitute to insulin injections.

Who Are the Leading Market Players Fueling Growth in the Non-injectable Insulin Market Trend?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

How is the Global Non-injectable Insulin Market Segemented?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Which Geographics are Influencing the Growth of the Non-injectable Insulin Market?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2025, By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Insulin Patch Pumps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Iron Deficiency Injectable Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the non-injectable insulin market grown in recent years?

The non-injectable insulin market has expanded significantly in recent years and is expected to increase from $1.92 billion in 2024 to $2.16 billion in 2025 at a CAGR of 12.1%. Key factors driving past growth include enhanced patient compliance, addressing needle phobia, improved quality of life, easier administration, and better blood glucose control.

How is the non-injectable insulin market size expected to evolve during the forecast period?

The non-injectable insulin market is projected to experience rapid expansion in the coming years, reaching $3.17 billion in 2029 at a CAGR of 10.1%. Growth factors include a strong focus on patient compliance, ongoing solutions for needle phobia, enhanced quality of life, improved safety measures, and reduced infection and injury risks. Key trends include technological advancements, digital health integration, nanotechnology applications, and combination therapies.

Get your non-injectable insulin market report here!

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

Which key drivers are propelling the non-injectable insulin market’s growth?

The growing prevalence of obesity and diabetes is anticipated to drive the expansion of the non-injectable insulin market. Obesity results from an imbalance between calorie intake and expenditure, leading to excessive fat accumulation, while diabetes is a group of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin plays a key role in managing both conditions by improving adherence, aiding weight management, and offering convenient treatment alternatives. For example, in 2022, the World Heart Federation reported that global obesity rates were rising, with 2.3 billion individuals—both children and adults—classified as overweight or obese in 2021, a number expected to reach 2.7 billion by 2025. Additionally, an April 2023 report from the British Diabetic Association indicated that 4.3 million people in the UK have diabetes, while over 2.4 million are at high risk of developing type 2 diabetes. The 2021-22 registration figures saw an increase of 148,951 from the previous year. Consequently, the increasing rates of obesity and diabetes are fueling the non-injectable insulin market’s growth.

What are the market segments in the non-injectable insulin industry?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Which leading companies are shaping the growth of the non-injectable insulin market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What key trends are currently impacting the non-injectable insulin market’s development?

Major players in the non-injectable insulin market are concentrating their efforts on the innovation of drug delivery technologies, such as needle-free oral insulin sprays, in order to enhance the quality of life of individuals who need to manage their diabetes with multiple insulin injections. A needle-free insulin spray offers an uncomplicated and painless method for controlling blood sugar levels, as doses can be administered directly into the mouth. To illustrate, NiedlFree Technologies, an Indian technology firm, launched Ozulin, an oral insulin spray, in November 2023. Designed to be more user-friendly and beneficial for those who struggle with traditional injectable insulin procedures, this spray is particularly aimed at diabetics. Should it gain approval, Ozulin could revolutionise the experience of diabetes patients, providing a pain-free and more practical substitute for insulin injections.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

Which geographic areas are influencing the growth of the non-injectable insulin market?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Insulin Patch Pumps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Iron Deficiency Injectable Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Future CAGR is Anticipated for the Non-injectable Insulin Market Over the 2025–2034 Period?

The market for non-injectable insulin has seen a swift expansion in the past few years. Its growth is projected to increase from $1.92 billion in 2024 to $2.16 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.1%. The substantial growth during the past period results from enhanced patient compliance, the management of needle phobia, betterment in quality of life, simplicity in administration, and consistent control of blood glucose levels.

The market for non-injectable insulin is anticipated to witness a swift expansion in the forthcoming years, achieving a size of $3.17 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.1%. The predicted growth during the forecast period can be ascribed to the ongoing focus on patient adherence, enduring solutions for needle fear, advancements in quality of life, sustained safety upgrades, and decreasing the risk of infections and injuries. The forecast period is also expected to see significant trends such as technical innovations, the progression of technological solutions, integration of digital health, nanotechnology incorporations, and combined treatments.

Which Drivers Are Expected to Have the Greatest Impact on the Non-injectable Insulin Market’s Growth?

The surge in obesity and diabetes problems is anticipated to stimulate the expansion of the non-injectable insulin market. Obesity is defined by an overabundance of body fat resulting from a discrepancy between energy consumption and expenditure, while diabetes often classified as a set of metabolic disorders, causes elevated blood sugar levels over an extended period. Non-injectable insulin is employed to treat both conditions and presents the potential to enhance disease management, by easing impediments to insulin therapy, offering possible weight management advantages and introducing more user-friendly treatment options. For example, the World Heart Federation, a Switzerland-based NGO, predicted in 2022 that global obesity rates would escalate, with an estimated 2.3 billion people, including children and adults being overweight or obese in 2021, and this figure is expected to rise to 2.7 billion by 2025. Additionally, a report by the UK-based charity, British Diabetic Association in April 2023, revealed that out of the 4.3 million people diagnosed with diabetes in the UK, over 2.4 million are highly susceptible to type 2 diabetes. The registration numbers for the year 2021-22 have observed a surge of 148,951 compared to the prior year. Thus, the growing prevalence of obesity and diabetes is fuelling the development of the non-injectable insulin market.

Get Your Free Sample of the Global Non-injectable Insulin Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

Who Are the Influential Players Fueling Innovation and Growth in the Non-injectable Insulin Market?

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

What Impact Are Industry Trends Having on the Non-injectable Insulin Market’s Future Prospects?

Major players in the non-injectable insulin market are concentrating their efforts on the innovation of drug delivery technologies, such as needle-free oral insulin sprays, in order to enhance the quality of life of individuals who need to manage their diabetes with multiple insulin injections. A needle-free insulin spray offers an uncomplicated and painless method for controlling blood sugar levels, as doses can be administered directly into the mouth. To illustrate, NiedlFree Technologies, an Indian technology firm, launched Ozulin, an oral insulin spray, in November 2023. Designed to be more user-friendly and beneficial for those who struggle with traditional injectable insulin procedures, this spray is particularly aimed at diabetics. Should it gain approval, Ozulin could revolutionise the experience of diabetes patients, providing a pain-free and more practical substitute for insulin injections.

Get Instant Access to the Global Non-injectable Insulin Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

What Are the Major Categories and Their Growth Dynamics in the Non-injectable Insulin Market?

The non-injectable insulin market covered in this report is segmented –

1) By Type: Synthetic Insulin, Semi Synthetic Insulin

2) By Product: Pills, Sprays, Other Products

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin

2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

What Regions Are Leading the Growth Trajectory of the Non-injectable Insulin Market?

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Characteristics That Define the Non-injectable Insulin Market?

Non-injectable insulin is a type of insulin that can be administered into the body without the need for injection. These non-injectable forms of insulin aim to offer alternatives to traditional injections, making diabetes management more accessible and potentially improving the overall quality of life for individuals with diabetes.

Browse Through More Similar Reports By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Insulin Patch Pumps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report

Iron Deficiency Injectable Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: